Vimian Group AB

Vimian Group AB

VIMIAN · ST · Healthcare / Diagnostics & Research

42.45SEK+0.20 (+0.47%)

Price History

Full chart

Market Stats

Previous Close42.25
Open42.30
Day Range42.25 – 42.75
52-Week Range24.18 – 36.45
Volume453.91K
Market Cap19.01B
P/E (TTM)54.55
Forward P/E0.00
EPS0.66
Dividend Yield0.00%
Beta1.13
50-Day Avg35.02
200-Day Avg30.46

About

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Alireza Tajbakhsh
  • Employees1.30K
  • HeadquartersRiddargatan 19, Stockholm, Sweden, 11457, Sweden
  • Websitehttps://vimian.com

Leadership

  • Mr. Alireza TajbakhshChief Executive Officer · b. 1983
  • Mr. Carl-Johan Zetterberg BoudrieDeputy CEO, CFO & Interim Head of Specialty Pharma · b. 1978
  • Ms. Maria Dahllof TullbergHead of IR, Communications & Sustainability · b. 1981
  • Mr. Carl-Johan EhnGeneral Counsel · b. 1974
  • Mr. Bart BremerChief People Officer · b. 1985
  • Mr. Magnus KjellbergChief Executive Officer of Nextmune · b. 1973
  • Mr. Stefano SantarelliHead of Diagnostics · b. 1981
  • Michael ThunellHead of Veterinary Services
  • Ms. Lotta LundaasHead of MedTech

Financials

Income Statement

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.10M24.53M137.75M173.35M281.31M331.73M374.80M425.00M
Growth (%)-+202.74%+461.54%+25.84%+62.28%+17.92%+12.98%+13.39%
Cost of Revenue3.50M9.10M42.24M50.50M87.31M102.30M116.50M132.20M
Gross Profit4.60M15.43M95.52M122.85M193.99M229.43M258.30M292.80M
Gross Margin56.76%62.91%69.34%70.87%68.96%69.16%68.92%68.89%
Operating Expense5.67M14.17M20.71M101.25M154.63M188.16M209.10M219.25M
Operating Income-1.07M1.26M74.80M21.60M39.36M41.27M49.20M73.55M
Operating Margin-13.24%5.15%54.30%12.46%13.99%12.44%13.13%17.31%
EBITDA-83.00K4.06M65.16M36.16M39.20M69.19M82.80M104.70M
EBITDA Margin-1.02%16.54%47.30%20.86%13.94%20.86%22.09%24.64%
Net Income-790.00K-1.23M52.79M6.59M-7.20M9.84M18.50M31.30M
Net Income Margin-9.75%-5.00%38.33%3.80%-2.56%2.97%4.94%7.36%
R&D---2.41M8.36M5.67M--
R&D as % of Total Revenue---1.39%2.97%1.71%--
Interest Expense214.00K400.00K7.17M6.72M11.05M19.25M25.40M21.09M
Interest Expense % of Total Revenue2.64%1.63%5.21%3.87%3.93%5.80%6.78%4.96%

Balance Sheet

Currency: EUR2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.00K33.24M99.10M456.29M640.72M923.56M973.68M1.11B1.11B
Total Liabilities013.65M47.08M182.05M282.08M442.06M446.97M403.30M401.00M
Total Equity5.00K19.16M40.91M224.02M357.41M481.81M526.37M699.90M698.90M
Cash5.00K1.54M12.04M29.66M55.11M42.19M37.50M64.80M55.00M
Total Debt-6.74M15.47M85.91M180.37M220.96M313.80M233.60M238.70M
Net Debt-5.00K5.20M3.43M56.24M125.25M178.76M276.30M168.80M183.70M

Cash Flow

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.02M1.55M4.80M16.01M25.31M-28.58M58.10M105.70M
Investing Cash Flow-22.54M-37.29M-105.24M-115.00M-188.53M-77.68M-76.00M-112.80M
Financing Cash Flow26.10M46.34M118.57M123.94M150.23M100.55M44.80M-1.20M
Capital Expenditure279.00K1.08M5.59M11.49M10.31M14.90M14.20M15.10M
Free Cash Flow-2.30M467.00K-793.00K4.52M15.01M-43.48M43.90M90.60M
FCF to OCF113.78%30.17%-16.52%28.24%59.28%152.16%75.56%85.71%

Earnings

Report DateAug 25, 2021Nov 26, 2021Mar 10, 2022May 24, 2022Aug 24, 2022Nov 16, 2022Mar 8, 2023May 4, 2023Aug 17, 2023Nov 8, 2023Feb 15, 2024May 2, 2024Aug 15, 2024Oct 24, 2024Feb 13, 2025Apr 29, 2025Jul 18, 2025Oct 22, 2025Feb 12, 2026Apr 29, 2026Jul 16, 2026Oct 22, 2026
EPS Estimate0.020.020.030.030.020.020.050.030.010.010.020.030.020.020.020.020.030.020.020.030.030.03
EPS Actual0.010.010.020.020.040.01-0.040.020.010.020.020.020.020.010.030.020.020.010.020.020.02-
Surprise-50.00%-50.00%-33.33%-33.33%100.00%-50.00%-180.00%-33.33%0.00%100.00%0.00%-33.33%0.00%-50.00%62.75%0.00%-33.33%-50.00%0.00%-33.33%-33.33%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap19.01B
Enterprise Value21.41B
Trailing P/E54.55
Forward P/E0.00
Price / Sales42.16
Price / Book2.28
EPS0.66
Book Value1.39
Revenue (TTM)450.90M
Gross Profit (TTM)310.30M
EBITDA114.20M
Profit Margin8.16%
Operating Margin18.42%
Return on Equity5.27%
Return on Assets4.36%
Shares Outstanding527.31M
Shares Float186.18K
Beta1.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Mar 14, 2024536:519